Concepedia

Author

David H. Vesole

Dana-Farber Cancer Institute

Also Known As

D H Vesole, D Vesole, D. H. Vesole, D. Vesole, Dav H. Vesole, David H Vesole, David H. Vesole, David Vesole, Karin Vanderkerken

95

Publications

11.9K

Citations

34

H-Index

45

Concepts

All Affiliations

Dana-Farber Cancer InstituteHackensack University Medical CenterMayo Clinic in ArizonaMedical College of WisconsinMayo Clinic
DH

About

David H. Vesole is an author at Dana-Farber Cancer Institute specializing in medicine, hematology, and health sciences.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

13

15

3.7K

2

Health Sciences

7

7

586

3

Blood Transplantation

4

4

235

4

Cell Biology

2

2

282

5

Cellular Therapies

1

1

66

David H. Vesole

×

41

Publications

7.8K

Citations

29

H-Index

YearCitations

International uniform response criteria for multiple myeloma

Brian G.M. Durie, J-L Harousseau, Jesús F. San Miguel,

Leukemia

2006

2.6K

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

S. Vincent Rajkumar, Jean‐Luc Harousseau, Brian G.M. Durie,

Blood

2011

1K

Phase III Clinical Trial of Thalidomide Plus Dexamethasone Compared With Dexamethasone Alone in Newly Diagnosed Multiple Myeloma: A Clinical Trial Coordinated by the Eastern Cooperative Oncology Group

S. Vincent Rajkumar, Emily Blood, David H. Vesole,

Journal of Clinical Oncology

2005

871

International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment

Meletios Α. Dimopoulos, Pieter Sonneveld, Nelson Leung,

Journal of Clinical Oncology

2016

404

International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation

Michèle Cavo, S. Vincent Rajkumar, Antonio Palumbo,

Blood

2011

312

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma

Ravi Vij, Michael Wang, Jonathan L. Kaufman,

Blood

2012

254

Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens

Shaji Kumar, Sergio Giralt, Edward A. Stadtmauer,

Blood

2009

230

Transactivation of a human cytomegalovirus early promoter by gene products from the immediate-early gene IE2 and augmentation by IE1: mutational analysis of the viral proteins

Cheryl L. Malone, David H. Vesole, Mark F. Stinski

Journal of Virology

1990

216

American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma

Sergio Giralt, Laurent Garderet, Brian G.M. Durie,

Biology of Blood and Marrow Transplantation

2015

162

International Myeloma Working Group Consensus Statement Regarding the Current Status of Allogeneic Stem-Cell Transplantation for Multiple Myeloma

Henk M. Lokhorst, Hermann Einsele, David H. Vesole,

Journal of Clinical Oncology

2010

161

Page 1